Target intelligence / Profile preview

Grainyhead-like transcription factor 3 (GRHL3)

Target
GRHL3
Molecular classification
Transcription factor, DNA-binding protein, Pioneer factor (transcriptional pioneer factor)
01

Overview

Grainyhead-like transcription factor 3 (GRHL3) is a member of the highly conserved grainyhead transcription factor family, functioning as a DNA-binding transcription factor with a crucial role in multiple developmental processes, especially the differentiation and maintenance of stratified epithelial tissues. It directly binds distinct cis-regulatory DNA elements and can both activate and repress gene networks critical for epidermal barrier formation, wound repair, and neurulation. GRHL3 is also recognized as a pioneer factor, able to remodel chromatin to establish an epithelial transcriptional landscape and facilitate cellular differentiation. Loss-of-function mutations or dysregulation of GRHL3 are implicated in various developmental defects (e.g., cleft palate, neural tube defects, Van der Woude syndrome), as well as tumorigenesis, particularly through modulation of cell adhesion, migration, and the epithelial-mesenchymal transition. In cancer, GRHL3 most notably acts as a tumor suppressor in squamous cell carcinomas by regulating PTEN and other differentiation-related genes.

Other names
Grainyhead-like protein 3 homologSister of mammalian grainyheadTranscription factor CP2-like 4SOMTFCP2L4VWS2transcription factor hSOM1
02

Mechanism of action

Not applicable (no direct drug mechanisms currently established for specific GRHL3 targeting)

03

Biological functions

Regulation of embryonic developmentEpithelial differentiationFormation and maintenance of epidermal and epithelial barriersChromatin remodelingRegulation of gene expression (activator and repressor roles)Wound healing and repairSuppression of epithelial-mesenchymal transitionCell migration
04

Disease associations

Cancer (notably acts as a tumor suppressor in squamous cell carcinoma)Van der Woude syndrome 2Isolated cleft palateNeural tube defectsSyndactyly (digit fusion)Bladder epithelial dysfunction
05

Safety considerations

Potential for off-target effects in therapeutic strategies altering GRHL3 due to its widespread role in epithelial and developmental processesDisruption may lead to skin barrier defects, impaired wound healing, and developmental abnormalities
06

Biomarkers

GRHL3 gene/protein expression (indicator in some cancers, developmental disorders, and as a lineage marker in epithelial cell studies)

Beyond the preview

Go deeper on Grainyhead-like transcription factor 3 (GRHL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grainyhead-like transcription factor 3 (GRHL3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call